5.09
2.21%
0.11
After Hours:
5.09
Eliem Therapeutics Inc stock is traded at $5.09, with a volume of 735.48K.
It is up +2.21% in the last 24 hours and down -27.18% over the past month.
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its main drug candidate is ETX-155 for major depressive disorder (MDD) and focal onset seizures (FOS).
See More
Previous Close:
$4.98
Open:
$4.99
24h Volume:
735.48K
Relative Volume:
1.61
Market Cap:
$342.01M
Revenue:
-
Net Income/Loss:
$-64.20M
P/E Ratio:
-3.0118
EPS:
-1.69
Net Cash Flow:
$57,000
1W Performance:
-33.29%
1M Performance:
-27.18%
6M Performance:
+85.77%
1Y Performance:
+93.54%
Eliem Therapeutics Inc Stock (ELYM) Company Profile
Name
Eliem Therapeutics Inc
Sector
Industry
Phone
877-354-3689
Address
2801 CENTERVILLE ROAD 1ST FLOOR, WILMINGTON
Eliem Therapeutics Inc Stock (ELYM) Latest News
Eliem Therapeutics Inc (ELYM) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Ratio Analysis: Unpacking Eliem Therapeutics Inc (ELYM)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Eliem Therapeutics, Inc. (NASDAQ:ELYM) Shares Sold by Driehaus Capital Management LLC - MarketBeat
Selling Eliem Therapeutics Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - Simply Wall St
Private equity firms who have a significant stake must be disappointed along with institutions after Eliem Therapeutics, Inc.'s (NASDAQ:ELYM) market cap dropped by US$231m - Yahoo Finance
Eliem Therapeutics Inc (ELYM) can make a big difference with a little luck - SETE News
Eliem Therapeutics Inc (ELYM) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Affinity Asset Advisors LLC Takes $11.88 Million Position in Eliem Therapeutics, Inc. (NASDAQ:ELYM) - MarketBeat
Trading (ELYM) With Integrated Risk Controls - Stock Traders Daily
500,000 Shares in Eliem Therapeutics, Inc. (NASDAQ:ELYM) Acquired by Ally Bridge Group NY LLC - MarketBeat
Eliem Therapeutics: Recent Strategic Pipeline Restructuring (NASDAQ:ELYM) - Seeking Alpha
Closing Figures: Eliem Therapeutics Inc (ELYM)’s Positive Finish at 8.43, Up 1.81 - The Dwinnex
Eliem Therapeutics Inc (ELYM)’s stock price in review: A technical analysis - US Post News
Eliem therapeutics executive sells over $9,000 in company stock - Investing.com
Eliem therapeutics executive sells over $9,000 in company stock - Investing.com India
Eliem therapeutics executive sells over $9,000 in company stock By Investing.com - Investing.com Canada
(ELYM) Trading Signals - Stock Traders Daily
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit - GlobeNewswire
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit - StockTitan
Eliem Therapeutics (NASDAQ:ELYM) Trading Up 4.6% - MarketBeat
Eliem Therapeutics Inc [ELYM] Investment Appeal on the Rise - Knox Daily
ELYM’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
A Guide To The Risks Of Investing In Eliem Therapeutics Inc (ELYM) - Knox Daily
Eliem Therapeutics appoints Kaplan as COO; Rampal as SVP, Clinical Development - MSN
Eliem Therapeutics announces executive changes, refocuses on autoimmune diseases - Investing.com India
Eliem Therapeutics announces executive changes, refocuses on autoimmune diseases - Investing.com
Eliem Therapeutics: Executive Changes Amid Strategic Shift - TipRanks
Eliem Therapeutics expands executive team with new COO and SVP - Investing.com
Eliem Therapeutics appoints new COO Brett Kaplan - Investing.com
Eliem Therapeutics expands executive team with new COO and SVP - Investing.com India
Eliem Therapeutics appoints new COO Brett Kaplan By Investing.com - Investing.com UK
Eliem Therapeutics Names Brett Kaplan as New COO - TipRanks
Eliem Therapeutics Announces Additions to its Leadership Team - GlobeNewswire
Eliem Therapeutics Announces Additions to its Leadership Team - GlobeNewswire Inc.
ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q2 2024 - MSN
(ELYM) Long Term Investment Analysis - Stock Traders Daily
Eliem Therapeutics, Inc. (NASDAQ:ELYM) Short Interest Up 34.0% in July - Defense World
Eliem Therapeutics, Inc. (NASDAQ:ELYM) Short Interest Up 34.0% in July - MarketBeat
Analyzing Eliem Therapeutics Inc (ELYM) After Recent Trading Activity - Knox Daily
Eliem Therapeutics Reports Second Quarter Financial Results - ForexTV.com
Eliem Therapeutics Reports Second Quarter Financial Results - GlobeNewswire
Eliem Therapeutics Reports Second Quarter Financial Results - Yahoo Finance
Sciatica Treatment Industry is Expected to Reach Rapid Growth - openPR
ELYM’s 2023 Market Dance: Up 124.07% – Time to Invest? - The InvestChronicle
Daily Progress: Eliem Therapeutics Inc (ELYM) Drop -15.50, Closing at 6.05 - The Dwinnex
Recent Insider Activity Could Benefit Eliem Therapeutics Inc (ELYM) - Knox Daily
How To Trade (ELYM) - Stock Traders Daily
Where are the Opportunities in (ELYM) - Stock Traders Daily
Eliem Therapeutics, Inc. (NASDAQ:ELYM) Sees Significant Growth in Short Interest - MarketBeat
Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Valerie Morisset Sells 60,201 Shares - Defense World
Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Valerie Morisset Sells 69,005 Shares - Defense World
Eliem Therapeutics Inc Stock (ELYM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):